Recently, Paroni G. et al. showed that HER2–positive breast cancer cells were sensitive to KDM5 inhibition and KDM5 inhibitors exhibited a synergistic effect with HER2 targeting drugs, trastuzumab and lapatinib [32]. The gene discussed is ERBB2; the disease is breast cancer.